ClinicalTrials.gg
CompletedNCT01314118Updated Feb 24, 2026Results posted

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

A Phase 2 interventional study of abiraterone acetate in combination with prednisone in Prostate Cancer and Prostatic Neoplasm, sponsored by Janssen Biotech, Inc.. Completed at 45 sites in United States. Open to male participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by Janssen Biotech, Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
131
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.

Enrollment
24th of 98
131 · median 56
Started
2011
with 4 others
Phase 2
59 of 98
9 open now
Registered
14th of 98
by date

Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 24th largest by enrollment, is one of 5 that started in 2011, is one of 59 in phase 2, and was the 14th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Abiraterone Acetate

Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 99 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to show that abiraterone acetate plus prednisone added to the current standard of care, gonadotropin-releasing hormone (GnRH) decreases prostate specific antigen (PSA) and prolongs the time until it is evident that the cancer has grown. Additionally, safety information about abiraterone acetate in combination with prednisone will be collected. This will include looking at what side effects occur, how often they occur, and for how long they last.

Read the detailed description

This is a Phase 2, prospective, multicenter, open-label, single-arm study of abiraterone acetate plus prednisone in men with non-metastatic, castration-resistant prostate cancer (CRPC) who have a rising PSA despite castrate levels of testosterone. The study consists of Screening Phase (up to 4 weeks), Core Study Treatment Phase (comprised of six 28-day cycles), a Pre-metastatic Disease Follow-up Phase, an Optional Drug Holiday Phase; and a 30-day Safety Follow-up Visit. Each treatment cycle will last 28 days. Participating participants will receive study agents (Abiraterone acetate 1000 mg/day plus prednisone 5 mg/day, orally) continually during the study. If the partcipants elects to participate in the Optional Drug Holiday Phase, participants will discontinue abiraterone acetate plus prednisone and ADT. Participants will have the option to return to study medication during the first year of the Optional Drug Holiday Phase if there is evidence of rising PSA but no metastasis based on study imaging. If participants do no elect to participate, they will continue with the core study treatment as per protocol. The study will end when all participated participants have disease progression or end of the 2-year period (if participants participated in the Optional Drug Holiday Phase). Participants will be required to return to the study site 30 days after receiving the last dose of abiraterone acetate for safety follow-up.

03

Conditions studied

  • Prostate Cancer
  • Prostatic Neoplasm

Browse trials for

Keywords

  • abiraterone acetate
  • prednisone
  • zytiga
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  • Be a male >= 18 years of age
  • Have adenocarcinoma of the prostate
  • Currently receiving continuous treatment with Gonadotropin-releasing hormone (GnRH) monotherapy for at least 6 months before or have undergone surgical removal of the testicles
  • Serum testosterone of \< 50 ng/dL(\< 2.0 nM)
  • Have rising PSA defined as a PSA of >= 10 ng/mL obtained at screening or PSADT of ≤ 10 months with the first of the 3 consecutive PSA values used to calculate PSADT ≥ 2.0 ng/mL
  • Have an (ECOG) performance status less than or equal to 2
  • Be capable of swallowing study agents whole as a tablet
  • Be willing/able to adhere to the prohibitions and restrictions specified in this protocol

Major Exclusion Criteria:

  • Have prior or current evidence of local disease progression or disease as defined by modified (RECIST) criteria
  • Have received chemotherapy for treatment of castrate-resistant prostate cancer; however, if a patient received chemotherapy in an setting, prior to having CRPC, for castrate-sensitive prostate cancer, the patient is still eligible
  • Are currently receiving any antiandrogen therapy (eg, bicalutamide, flutamide, or nilutamide).
  • If previously treated with antiandrogen therapy, there must be documentation of at least 2 consecutive rising PSA values at least 2 weeks apart obtained prior to screening
  • If previously treated with flutamide, at least 1 of the PSA values must be obtained 4 weeks or more after flutamide discontinuation.
  • If previously treated with bicalutamide or nilutamide, at least 1 of the PSA values must be obtained 6 weeks or more after antiandrogen discontinuation
  • Have previously received agents having any CYP17 inhibitory activity for the treatment of prostate cancer, such as ketoconazole
  • Have previously received aminoglutethimide
  • Have an active infection or other medical condition that would contraindicate prednisone use
  • Have uncontrolled hypertension
  • Have active hepatitis or chronic liver disease
  • Have heart disease
  • Have poorly controlled diabetes
  • Have received an therapeutic within 30 days of screening
  • Have partners of and are not willing to use a method of with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 1 week after last dose of abiraterone acetate.
  • Individuals with a history of a non-prostate are ineligible for this study with the following exceptions. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 3 years: basal cell or squamous cell carcinoma of the skin
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    001

    abiraterone acetate in combination with prednisone Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.

    Drug: abiraterone acetate in combination with prednisone

Interventions

  • Drugabiraterone acetate in combination with prednisone

    Drug pages: Abiraterone Acetate · Prednisone

    Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) During the Core Study

    Percentage of participants with greater than or equal to 50 percent decrease in PSA levels was assessed.

    Time frame: End of core study visit (Approximately at Month 6)

Secondary outcomes

  1. Time to Radiographic Evidence of Disease Progression (TTRP)

    Time to radiographic evidence of disease progression is defined as the time interval from the date of enrollment (Day 1) to the date of disease progression. A participant was considered as progressed by bone scan if: 1) The appearance of greater than or equal to (\>=) 2 new lesions, and, following the first assessment, a confirmatory scan performed 6 or more weeks later that shows a minimum of 2 or more additional new lesions, 2) If \>=2 new lesions are seen on scans following the first assessment, the confirmation is still required after 6 weeks; however, 2 addition lesions are not required to confirm progression, and 3) The date of progression is the date of the first scan that shows the changes.

    Time frame: Maximum up to Month 30.5

  2. Time to Prostate-Specific Antigen (PSA) Progression

    Time to PSA progression is defined as the time interval from the date of enrollment (Day 1) to the date of first evidence of PSA progression. A participant was considered to have a PSA progression if the PSA level had a 25 percent (%) or greater increase and an absolute increase of 2 nanogram (ng)/milliliter (mL) or more, which is confirmed by a second value obtained in 3 or more weeks.

    Time frame: Maximum up to Month 30.5

  3. Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) Levels After 3 Cycles of Treatment

    Percentage of participants with greater than or equal to 50 percent decrease in PSA levels was assessed. Decrease in PSA levels represented improvement.

    Time frame: End of Cycle 3 (Approximately Month 3)

07

Results

Posted Jan 7, 2015

Participant flow

Participant flow — Overall Study
MilestoneAbiraterone Acetate Plus Prednisone
Started131
Completed until treatment cycle 6112
Completed47
Not completed84
Withdrew: Adverse event10
Withdrew: Progressive disease3
Withdrew: Death8
Withdrew: Physician decision13
Withdrew: Sponsor decision1
Withdrew: Protocol violation2
Withdrew: Withdrawal by subject26
Withdrew: Other21

Outcome measures

PrimaryPercentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) During the Core Study

Percentage of participants with greater than or equal to 50 percent decrease in PSA levels was assessed.

Time frame:
End of core study visit (Approximately at Month 6)
Reported as:
Number · Percentage of participants
Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) During the Core Study
Percentage of participantsAbiraterone Acetate Plus Prednisone
Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) During the Core Study86.9 (80.9 to 92.9)
SecondaryTime to Radiographic Evidence of Disease Progression (TTRP)

Time to radiographic evidence of disease progression is defined as the time interval from the date of enrollment (Day 1) to the date of disease progression. A participant was considered as progressed by bone scan if: 1) The appearance of greater than or equal to (\>=) 2 new lesions, and, following the first assessment, a confirmatory scan performed 6 or more weeks later that shows a minimum of 2 or more additional new lesions, 2) If \>=2 new lesions are seen on scans following the first assessment, the confirmation is still required after 6 weeks; however, 2 addition lesions are not required to confirm progression, and 3) The date of progression is the date of the first scan that shows the changes.

Time frame:
Maximum up to Month 30.5
Reported as:
Median · Months
Time to Radiographic Evidence of Disease Progression (TTRP)
MonthsAbiraterone Acetate Plus Prednisone
Time to Radiographic Evidence of Disease Progression (TTRP)41.4 (27.6 to NA)
SecondaryTime to Prostate-Specific Antigen (PSA) Progression

Time to PSA progression is defined as the time interval from the date of enrollment (Day 1) to the date of first evidence of PSA progression. A participant was considered to have a PSA progression if the PSA level had a 25 percent (%) or greater increase and an absolute increase of 2 nanogram (ng)/milliliter (mL) or more, which is confirmed by a second value obtained in 3 or more weeks.

Time frame:
Maximum up to Month 30.5
Reported as:
Median · Months
Time to Prostate-Specific Antigen (PSA) Progression
MonthsAbiraterone Acetate Plus Prednisone
Time to Prostate-Specific Antigen (PSA) Progression28.7 (21.2 to 38.2)
SecondaryPercentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) Levels After 3 Cycles of Treatment

Percentage of participants with greater than or equal to 50 percent decrease in PSA levels was assessed. Decrease in PSA levels represented improvement.

Time frame:
End of Cycle 3 (Approximately Month 3)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) Levels After 3 Cycles of Treatment
Percentage of ParticipantsAbiraterone Acetate Plus Prednisone
Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) Levels After 3 Cycles of Treatment85.2 (79.0 to 91.5)

Adverse events

Collected over All-cause mortality: From screening (-28 days) up to 141 months; Serious and Other AEs: From Cycle 1 Day 1 up to 30 days after last dose (up to 141 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abiraterone Acetate Plus Prednisone11/131 (8.4%)61/131 (46.6%)120/131 (91.6%)
Most frequent serious events
Showing 10 of 93
Most frequent serious events
EventAbiraterone Acetate Plus Prednisone
PneumoniaInfections and infestations8/131
SepsisInfections and infestations7/131
UrosepsisInfections and infestations5/131
SyncopeNervous system disorders5/131
Urinary RetentionRenal and urinary disorders5/131
Coronary Artery DiseaseCardiac disorders4/131
Urinary Tract InfectionInfections and infestations4/131
Alanine Aminotransferase IncreasedInvestigations4/131
Atrial FibrillationCardiac disorders3/131
FallInjury, poisoning and procedural complications3/131
Most frequent other events
Showing 10 of 59
Most frequent other events
EventAbiraterone Acetate Plus Prednisone
HypertensionVascular disorders58/131
FatigueGeneral disorders56/131
HypokalaemiaMetabolism and nutrition disorders44/131
Oedema PeripheralGeneral disorders34/131
DiarrhoeaGastrointestinal disorders27/131
NauseaGastrointestinal disorders27/131
DizzinessNervous system disorders27/131
ConstipationGastrointestinal disorders25/131
HeadacheNervous system disorders25/131
CoughRespiratory, thoracic and mediastinal disorders25/131

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Abiraterone Acetate Plus Prednisone
Mean71.2 ± 8.82
Sex: Female, Male
Sex: Female, Male(Participants)Abiraterone Acetate Plus Prednisone
Female0
Male131
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Abiraterone Acetate Plus Prednisone
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American19
White108
More than one race0
Unknown or Not Reported2
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Abiraterone Acetate Plus Prednisone
Not Hispanic or Latino122
Unknown or Not Reported1
Hispanic or Latino8
Region of Enrollment
Region of Enrollment(Participants)Abiraterone Acetate Plus Prednisone
United States131
08

Study locations

45 sites
  • Homewood, Alabama, United States
  • Huntsville, Alabama, United States
  • Tucson, Arizona, United States
  • Los Angeles, California, United States
  • San Diego, California, United States
  • San Francisco, California, United States
  • Aurora, Colorado, United States
  • Denver, Colorado, United States
  • Aventura, Florida, United States
  • Orange City, Florida, United States
  • Atlanta, Georgia, United States
  • Evanston, Illinois, United States
  • Galesburg, Illinois, United States
  • Glenview, Illinois, United States
  • Melrose Park, Illinois, United States
  • Fort Wayne, Indiana, United States
  • Jeffersonville, Indiana, United States
  • New Orleans, Louisiana, United States
  • Baltimore, Maryland, United States
  • Rockville, Maryland, United States
  • Boston, Massachusetts, United States
  • Lansing, Michigan, United States
  • Omaha, Nebraska, United States
  • Lawrenceville, New Jersey, United States
  • Albany, New York, United States
  • Brooklyn, New York, United States
  • Buffalo, New York, United States
  • Garden City, New York, United States
  • New York, New York, United States
  • Poughkeepsie, New York, United States
  • Staten Island, New York, United States
  • Chapel Hill, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Lancaster, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Greenville, South Carolina, United States
  • Myrtle Beach, South Carolina, United States
  • Nashville, Tennessee, United States
  • Arlington, Texas, United States
  • Houston, Texas, United States
  • Seattle, Washington, United States
  • Milwaukee, Wisconsin, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2011 to primary completion in Dec 2013, 31 months.

Results were first posted in Jan 2015, 1 year after primary completion.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 31 months is below that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2011
First posted
Mar 14, 2011
StartActual
May 4, 2011
Primary completionActual
Dec 24, 2013
CompletionActual
Dec 2, 2024
Results first posted
Jan 7, 2015
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01314118
Responsible party
Sponsor
First posted
Mar 14, 2011
Start date
May 4, 2011
Primary completion
Dec 24, 2013
Completion
Dec 2, 2024
Results posted
Jan 7, 2015
Last update
Feb 24, 2026

Study contacts

Janssen Services, LLC. Clinical Trial
study director · Janssen Biotech, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abiraterone Acetate · Prednisone

Start the discussion